Reliability of core needle biopsy for determining ER and HER2 status in breast cancer

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 931-937

  Dekker, T J A ^a   Smit, V T H B M ^a   Hooijer, G K J ^b   Van de vijver, M J ^b   Mesker, W E ^a   Tollenaar, R A E M ^a   Nortier, J W R ^a   Kroep, J R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; Comparative study; Core needle biopsy; Estrogen receptor; Human epidermal growth factor 2; Resection specimen

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURGERY; CANCER TISSUE; CONTROLLED STUDY; CORE NEEDLE BIOPSY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; PATIENT CARE; PRIORITY JOURNAL; RELIABILITY; SCORING SYSTEM; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, LARGE-CORE NEEDLE; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TISSUE ARRAY ANALYSIS;

EID: 84875595972     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds599     Document Type: Article

References (35)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46(4): 765-781.
2. Berry DA, Cronin KA, Plevritis SK et al.. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353(17): 1784-1792.
3. Wolff AC, Hammond ME, Schwartz JN et al.. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25(1): 118-145.
4. Hammond ME, Hayes DF, Dowsett M et al.. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28(16): 2784-2795.
5. Al SW, Salhab M, Thomas V et al.. Is preoperative core biopsy accurate in determining the hormone receptor status in women with invasive breast cancer? Int Semin Surg Oncol 2005; 2: 15.
6. Arnedos M, Nerurkar A, Osin P et al.. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 2009; 20(12): 1948-1952.
7. Badoual C, Maruani A, Ghorra C et al.. Pathological prognostic factors of invasive breast carcinoma in ultrasound-guided large core biopsies-correlation with subsequent surgical excisions. Breast 2005; 14(1): 22-27.
8. Burge CN, Chang HR, Apple SK. Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens? Breast 2006; 15(2): 167-172.
9. Cahill RA, Walsh D, Landers RJ et al.. Preoperative profiling of symptomatic breast cancer by diagnostic core biopsy. Ann Surg Oncol 2006; 13(1): 45-51.
10. Cavaliere A, Sidoni A, Scheibel M et al.. Biopathologic profile of breast cancer core biopsy: is it always a valid method? Cancer Lett 2005; 218(1): 117-121.
11. Connor CS, Tawfik OW, Joyce AJ et al.. A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens. Am J Surg 2002; 184(4): 322-324.
12. Di LC, Puglisi F, Rimondi G et al.. Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas. Eur J Cancer 1996; 32A(10): 1693-1700.
13. Hodi Z, Chakrabarti J, Lee AH et al.. The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. J Clin Pathol 2007; 60(3): 299-302.
14. Khoury T, Zakharia Y, Tan W et al.. Breast hormonal receptors test should be repeated on excisional biopsy after negative core needle biopsy. Breast J 2011; 17(2): 180-186.
15. Lorgis V, Algros MP, Villanueva C et al.. Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour. Breast 2011; 20(3): 284-287.
16. Mann GB, Fahey VD, Feleppa F et al.. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 2005; 23(22): 5148-5154.
17. Ough M, Velasco J, Hieken TJ. A comparative analysis of core needle biopsy and final excision for breast cancer: histology and marker expression. Am J Surg 2011; 201(5): 692-694.
18. Ozdemir A, Voyvoda NK, Gultekin S et al.. Can core biopsy be used instead of surgical biopsy in the diagnosis and prognostic factor analysis of breast carcinoma? Clin Breast Cancer 2007; 7(10): 791-795.
19. Park SY, Kim KS, Lee TG et al.. The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer. Am J Surg 2009; 197(2): 266-269.
20. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1659-1672.
21. Railo M, Nordling S, Krogerus L et al.. Preoperative assessment of proliferative activity and hormonal receptor status in carcinoma of the breast: a comparison of needle aspiration and needle-core biopsies to the surgical specimen. Diagn Cytopathol 1996; 15(3): 205-210.
22. Richter-Ehrenstein C, Muller S, Noske A et al.. Diagnostic accuracy and prognostic value of core biopsy in the management of breast cancer: a series of 542 patients. Int J Surg Pathol 2009; 17(4): 323-326.
23. Sutela A, Vanninen R, Sudah M et al.. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer. Acta Oncol 2008; 47: 38-46.
24. Tamaki K, Sasano H, Ishida T et al.. Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients. Cancer Sci 2010; 101(9): 2074-2079.
25. Usami S, Moriya T, Amari M et al.. Reliability of prognostic factors in breast carcinoma determined by core needle biopsy. Jpn J Clin Oncol 2007; 37(4): 250-255.
26. Wood B, Junckerstorff R, Sterrett G et al.. A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions. Pathology 2007; 39(4): 391-395.
27. Zidan A, Christie Brown JS, Peston D et al.. Oestrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma. J Clin Pathol 1997; 50(1): 27-29.
28. van de Ven S, Smit VT, Dekker TJ et al.. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev 2011; 37(6): 422-430.
29. Dekker TJA, Ter Borg S, Hooijer GKJ et al.. Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Research 2012; 14: R93.
30. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000; 80(12): 1943-1949.
31. Henriksen KL, Rasmussen BB, Lykkesfeldt AE et al.. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol 2007; 60(4): 397-404.
32. Apple SK, Lowe AC, Rao PN et al.. Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer. Mod Pathol 2009; 22(9): 1151-1159.
33. Tsuda H, Kurosumi M, Umemura S et al.. HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens. BMC Cancer 2010; 10: 534.
34. Lebeau A, Turzynski A, Braun S et al.. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. J Clin Oncol 2010; 28(20): 3264-3270.
35. Mueller-Holzner E, Fink V, Frede T et al.. Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HER2 status of the whole tumor. Breast Cancer Res Treat 2001; 69(1): 13-19.